Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Pre-randomization Inclusion Criteria: * Provide written informed consent before initiation of any study-related procedures. * Be at least 18 years of age * Be scheduled for cardiac surgery (including Coronary Artery Bypass Grafting \[CABG\], Off Pump Coronary Artery Bypass \[OPCAB\], Minimally Invasive Direct Coronary Artery Bypass \[MIDCAB\] surgery, and/or valve replacement/repair procedures) Pre-randomization Exclusion Criteria: * Women of child-bearing potential (unless they have a negative pregnancy test) * Recent cerebrovascular accident (within 3 months before randomization) * Known intolerance to calcium channel blockers * Allergy to soybean oil or egg lecithin (components of the lipid vehicle) * Pre-existing left bundle branch block or permanent ventricular pacing * Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial. * Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study Post-randomization Inclusion Criteria: * Expected to survive beyond 24 hours post-surgical procedure * No surgical complications or conditions, present or anticipated, that preclude them from inclusion in a double blind, placebo-controlled study * Determined to be hypertensive (SBP \> 140 mm Hg) within 4 hours of arrival in a postoperative setting * It is the investigator's intent to lower the patient's SBP by a minimum of 15% from its baseline value